NICE issues guidance on diabetes treatmentsBMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7414.520-d (Published 04 September 2003) Cite this as: BMJ 2003;327:520
- Andrew Iles
The use of thiazolidinediones (glitazones) for type 2 diabetes is to be restricted, after the release of new guidelines by the National Institute for Clinical Excellence (NICE).
NICE recommends that the treatment should be offered only to patients who cannot tolerate the combination treatment of metformin and a sulphonylurea. It no longer recommends glitazones to reduce blood glucose concentrations when treatment with metformin and a sulphonylurea has failed.
Glitazones directly target insulin resistance and preserve the (cells in the pancreas. Currently doctors in the United Kingdom prescribe glitazones in addition to combination treatment, …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial